{
  "abstract": "This was a monocentric prospective study testing the efficacy and safety of a first injection of BNT162b2 (Pfizer-BioNTech) in 112 Allo-HSCT patients. Antibody response to SARS-CoV-2 spike protein receptor-binding domain was tested at the time of the second injection (Roche Elecsys). The study also included a non-randomized control arm of 26 healthy controls. This study shows that a first dose of SARS-CoV-2 messenger RNA vaccine is safe and provides a 55% rate of seroconversion in allotransplanted patients compared to 100% for the controls (p < 0.001). Factors influencing the absence of response in patients were recent transplantation (<2 years), lymphopenia (<1 × 10 9 /L) and immunosuppressive treatment or chemotherapy at the time of vaccination.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": null,
  "arxiv": null,
  "author_total": 19,
  "authors": [
    {
      "name": "Patrice Chevallier"
    },
    {
      "name": "Marianne Coste‐burel"
    },
    {
      "name": "Amandine Le Bourgeois"
    },
    {
      "name": "Pierre Peterlin"
    },
    {
      "name": "Alice Garnier"
    },
    {
      "name": "Marie C Béné"
    },
    {
      "name": "Berthe‐marie Imbert"
    },
    {
      "name": "Thomas Drumel"
    },
    {
      "name": "Steven Le Gouill"
    },
    {
      "name": "Philippe Moreau"
    },
    {
      "name": "Beatrice Mahe"
    },
    {
      "name": "Viviane Dubruille"
    },
    {
      "name": "Nicolas Blin"
    },
    {
      "name": "Anne Lok"
    },
    {
      "name": "Cyrille Touzeau"
    },
    {
      "name": "Thomas Gastinne"
    },
    {
      "name": "Maxime Jullien"
    },
    {
      "name": "Sophie Vanthygem"
    },
    {
      "name": "Thierry Guillaume"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/19mgnxm0w77dw.bib",
  "cited_by": 35,
  "doi": "10.1002/jha2.242",
  "fulltext_url": null,
  "id": "19mgnxm0w77dw",
  "issns": [
    "2688-6146"
  ],
  "landing_url": "https://hal.science/hal-05753598v1",
  "language": "en",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "hal",
      "0.sdv"
    ],
    [
      "openalex",
      "2725|SARS-CoV-2 and COVID-19 Research"
    ]
  ],
  "openalex": "W3170463273",
  "pdf_url": "https://hal.science/hal-05753598/document",
  "pmcid": null,
  "pmid": "34226903",
  "published": "2026-09-17",
  "publisher": "Wiley",
  "ris": "https://research.draconitic.com/paper/19mgnxm0w77dw.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:17:36Z",
      "native_id": "hal-05753598",
      "source": "hal",
      "url": "https://hal.science/hal-05753598v1"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2725|SARS-CoV-2 and COVID-19 Research",
      "subfield": "infectious-disease"
    }
  ],
  "title": "Safety and immunogenicity of a first dose of SARS‐CoV‐2 mRNA vaccine in allogeneic hematopoietic stem‐cells recipients",
  "title_text": "Safety and immunogenicity of a first dose of SARS‐CoV‐2 mRNA vaccine in allogeneic hematopoietic stem‐cells recipients",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:17:36Z",
  "url": "https://research.draconitic.com/paper/19mgnxm0w77dw",
  "venue": "eJHaem",
  "versions": []
}